A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia

Published:2015-05-12 Issue:10 Volume:56 Page:2826-2833
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Kipps Thomas J.,Eradat Herbert,Grosicki Sebastian,Catalano John,Cosolo Walter,Dyagil Iryna S.,Yalamanchili Sreeni,Chai Akiko,Sahasranaman Srikumar,Punnoose Elizabeth,Hurst Deborah,Pylypenko Halyna

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2015.1030638

Reference28 articles.

1. Apoptosis Deregulation in CLL

2. BH3 Mimetics: Status of the Field and New Developments

3. An inhibitor of Bcl-2 family proteins induces regression of solid tumours

4. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737

Cited by 149 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of BCL-2 inhibitors and immunotherapy: a promising therapeutic strategy for hematological malignancies;Discover Oncology;2024-07-26

2. Directly targeting BAX for drug discovery: Therapeutic opportunities and challenges;Acta Pharmaceutica Sinica B;2024-06

3. The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment;Frontiers in Pharmacology;2024-04-16

4. Therapeutic targeting of apoptosis in chronic lymphocytic leukemia;Seminars in Hematology;2024-04

5. Antineoplastic Drug Synergy of Artesunate with Navitoclax in Models of High-Grade Serous Ovarian Cancer;Cancers;2024-03-28